FindTrial
Sign In

Clinical study of EUS-guided chemical ablation in the treatment of pancreatic precancerous disease IPMN

Clinical study of EUS-guided chemical ablation in the treatment of pancreatic precancerous disease IPMN

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059620
Enrollment
Unknown
Registered
2022-05-04
Start date
2022-06-07
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic IPMN

Interventions

1:Gemcitabine and paclitaxel ablation

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis: IPMN; 2. The lesion is larger than 1.5 cm; 3. Inability or refusal of surgery; 4. The age is greater than or equal to 18 years old and less than or equal to 75 years old; 5. Sign the informed consent to participate in this clinical study.

Exclusion criteria

Exclusion criteria: 1. Those who have contraindications to endoscopy; 2. Pregnant women.

Design outcomes

Primary

MeasureTime frame
complete resolution rate;—

Secondary

MeasureTime frame
adverse event rate;—

Countries

China

Contacts

Public ContactHuikai Li

Chinese PLA General Hospital

lihuikaihn@163.com+86 13718140120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026